• Looking for opportunities to accelerate your drug development?
  • Driving better decisions through quantitative methods
  • Innovation through global collaboration
Developing medicines is capital intensive and time sensitive.

Success can be fickle because of divergent views on value and piecemeal integration of expertise.

Thinking differently may make all the difference.

Introducing a company that may give your team the edge, in developing medicines that make a real difference.

d3 Medicine works collaboratively with like-minded and innovative people to improve their drug development process, with the guiding purpose of ensuring more meaningful medicines, reach patients globally.


  • Certara acquires d3 Medicine

    d3 Medicine’s strategic advisory and drug development capabilities expand Certara’s modeling and simulation and regulatory science powerhouse.

  • Webinar on “Early Development and Translational/Quantitative Pharmacology Strategies in Pediatric Drug Development”

    On 28th July, Craig Rayner and Patrick Smith will provide a Certara Webinar on “Early Development and Translational/Quantitative Pharmacology Strategies in Pediatric Drug Development”.

  • Craig Rayner delivers 2016 Monash University Graduation Address - "Job, Career or Vocation?"

    “It was a tremendous honour to present the 2016 Graduation Address to Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. I shared experiences from my own journey to highlight insights relating to Job, Career or Vocation," said Craig Rayner, CEO of d3 Medicine.

    Craig Rayner
  • d3 Medicine contributes to Clinical Cancer Research Focus section “New Approaches for Optimizing Dosing of Anticancer Agents”

    In collaboration with colleagues from the Food and Drug Administration (FDA), d3 Medicine published a review of lesson’s learned in dose optimization for small-molecule targeted anti-cancer agents in the June 1 issue of Clinical Cancer Research (CCR).

    Julie Bullock
  • d3 Medicine featured in Nature Biopharma Dealmakers

    d3 Medicine has been featured in Nature Biopharma Dealmakers in an article entitled “A turnkey, integrated solution for drug development strategies and stewardship”.

  • Translating innovative drug development strategy to value at the deal table

    Dr. Farrell emphasised the importance of earlier and stronger engagement in companies between development and business development teams in his presentation at the GTCBio 13th Anti-Infectives Partnering & Deal-Making Conference in San Diego.

    Leigh Farrell